Literature DB >> 20509340

A study of steroid-induced diabetes mellitus in leprosy.

R Papang1, A S John, S Abraham, P S S S Rao.   

Abstract

Steroids, while still the most powerful drugs to manage leprosy reactions, predispose some patients to other morbidities such as diabetes, glaucoma, hypertension etc. A prospective cohort study was done in Kolkata, India among leprosy patients in reaction to determine the extent of steroid induced diabetes mellitus (SID). All leprosy patients with type 1 or type 2 reactions or neuritis admitted in 2006 to the Leprosy Mission Hospital in Kolkata, who had no past or current history and whose blood sugars on fasting were <126 mg/dl or postprandial <200 mg/dl were monitored fortnightly while on steroid therapy, estimating blood glucose by a glucometer using standard strips. Of 81 patients, 19 (23.5%) manifested steroid-induced diabetes mellitus. Compared to those who didn't, there were significantly more LL/BL patients with positive BI among SID whose cumulative prednisolone dosage was nearly 9000 mg as compared to half the amount among others. Steroid induced diabetes is a serious complication among leprosy patients treated with prednisolone for reactions requiring careful monitoring for detection and appropriate clinical management.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20509340

Source DB:  PubMed          Journal:  Indian J Lepr        ISSN: 0254-9395


  3 in total

Review 1.  Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment.

Authors:  Jessica L Hwang; Roy E Weiss
Journal:  Diabetes Metab Res Rev       Date:  2014-02       Impact factor: 4.876

2.  Steroid induced diabetes mellitus in patients receiving prednisolone for haematological disorders.

Authors:  T R Kotila; T Olutogun; A Ipadeola
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

Review 3.  The global diabetes epidemic: what does it mean for infectious diseases in tropical countries?

Authors:  Reinout van Crevel; Steven van de Vijver; David A J Moore
Journal:  Lancet Diabetes Endocrinol       Date:  2016-08-04       Impact factor: 32.069

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.